Rigel anticipates 2025 total revenue of approximately $200M-$210M, including: Net product sales of approximately $185M-$192M; Contract revenues from collaborations of approximately $15M-$18M. The company anticipates it will report positive net income for the full year 2025, while funding existing and new clinical development programs. In addition, Rigel plans to initiate a Phase 2 clinical study in recurrent glioma in 2025.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RIGL:
- Rigel announces R289 granted Orphan Drug designation by FDA for MDS
- Rigel granted orphan status for myelodysplastic syndromes treatment
- Rigel Pharmaceuticals price target raised to $25 from $15 at Cantor Fitzgerald
- Rigel Pharmaceuticals price target lowered to $20 from $27 at B. Riley
- Rigel Pharmaceuticals announces initial data from Phase 1b study of R289